1. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Brief Overview.
- Author
-
Noel, Zachary R. and Beavers, Craig J.
- Subjects
- *
PROPROTEIN convertases , *SUBTILISINS , *ENZYME inhibitors , *LOW density lipoproteins , *DRUG interactions - Abstract
Proprotein convertase subtilisin/kexin type 9 inhibitors serve as a valuable addition to the armamentarium of lipid-lowering agents and have promising potential. By inhibiting the proprotein convertase subtilisin/kexin type 9 enzyme, this novel molecule leads to increased low-density lipoprotein receptor density and decreased circulation of low-density lipoprotein. The fact the agent is a monoclonal antibody has led to limited drug interactions and minimized adverse drug events. It is critical for all providers to have a basic understanding of these novel therapies with their introduction and use for treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF